MOLECULAR MEDICINE REPORTS 16: 238-246, 2017
238
Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy PEI LUO1*, QING YANG1*, LE‑LE CONG2*, XIAO‑FENG WANG3*, YU‑SHENG LI4, XIAO‑MING ZHONG5, RU‑TING XIE1, CHENG‑YOU JIA6, HUI‑QIONG YANG1, WEN‑PING LI1, XIAN‑LING CONG7, QING XIA3, DA FU6, QING‑HUA ZENG8 and YU‑SHUI MA6,9 1
College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128; 2Department of Neurology, China Japan Union Hospital, Jilin University, Changchun, Jilin 130031; 3Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai 200032; 4Department of Orthopedics, Xiangya Hospital, Central‑South University, Changsha, Hunan 410008; 5Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi 330029; 6Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072; 7Tissue Bank, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033; 8Department of Respiratory, The First Affiliated Hospital of Nanchang University, Nanchang 330006; 9Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China Received February 4, 2016; Accepted February 20, 2017 DOI: 10.3892/mmr.2017.6595 Abstract. Previous studies have suggested that dysregulation of microRNA (miR) ‑124a is associated with various types of human cancer. However, there are few studies reporting the level of miR‑124a expression in non‑small cell lung cancer (NSCLC). The present study investigated the association between miR‑124a and NSCLC by analyzing the differential expression of miR‑124a in NSCLC using the GEO database, as well as subsequently performing reverse transcription‑quantitative polymerase chain reaction analysis on 160 NSCLC biopsies, 32 of which were paired with adjacent normal tissues. The results indicated that mir‑124a expression levels were decreased in NSCLC tumor biopsies compared with adjacent normal tissues. The overall survival (OS) in patients with a high expression of miR‑124a was prolonged relative to patients with low expression of miR‑124a. The expression levels of miR‑124a were associated with clinical characteristics, including lymph‑node metastasis, tumor differentiation, tumor node metastasis (TNM) stage and diameter. Frequently,
Correspondence to: Dr Yu‑Shui Ma, Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai 200072, P.R. China E‑mail: [email protected] Dr Qing‑Hua Zeng, Department of Respiratory, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Road, Nanchang 330006, P.R. China E‑mail: [email protected] *
Contributed equally
Key words: microRNA‑124, non‑small cell lung cancer, chemotherapy, overall survival, disease‑free survival, biomarker, prognosis
lymph‑node metastasis, TNM stage, diameter and lack of chemotherapy have been associated with a worse prognosis in patients. In addition, the present study identified that high expression of miR‑124awith chemotherapy may increase OS. In conclusion, the current study demonstrated that miR‑124a was downregulated in NSCLC, and miR‑124a was a potential prognostic tumor biomarker response to chemotherapy. Introduction Lung cancer is one of the most common malignancies and is the major cause of cancer‑associated mortality, accounting for ~1.38 million deaths each year (1,2). Of all lung carcinomas, non‑small cell lung cancer (NSCLC) accounts for ~70‑85% (3). Although there have been recent advances in diagnosis and treatment, the prognosis of lung cancer is still unfavorable and the 5‑year overall survival (OS) rate remains
238
Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy PEI LUO1*, QING YANG1*, LE‑LE CONG2*, XIAO‑FENG WANG3*, YU‑SHENG LI4, XIAO‑MING ZHONG5, RU‑TING XIE1, CHENG‑YOU JIA6, HUI‑QIONG YANG1, WEN‑PING LI1, XIAN‑LING CONG7, QING XIA3, DA FU6, QING‑HUA ZENG8 and YU‑SHUI MA6,9 1
College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128; 2Department of Neurology, China Japan Union Hospital, Jilin University, Changchun, Jilin 130031; 3Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai 200032; 4Department of Orthopedics, Xiangya Hospital, Central‑South University, Changsha, Hunan 410008; 5Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi 330029; 6Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072; 7Tissue Bank, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033; 8Department of Respiratory, The First Affiliated Hospital of Nanchang University, Nanchang 330006; 9Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, P.R. China Received February 4, 2016; Accepted February 20, 2017 DOI: 10.3892/mmr.2017.6595 Abstract. Previous studies have suggested that dysregulation of microRNA (miR) ‑124a is associated with various types of human cancer. However, there are few studies reporting the level of miR‑124a expression in non‑small cell lung cancer (NSCLC). The present study investigated the association between miR‑124a and NSCLC by analyzing the differential expression of miR‑124a in NSCLC using the GEO database, as well as subsequently performing reverse transcription‑quantitative polymerase chain reaction analysis on 160 NSCLC biopsies, 32 of which were paired with adjacent normal tissues. The results indicated that mir‑124a expression levels were decreased in NSCLC tumor biopsies compared with adjacent normal tissues. The overall survival (OS) in patients with a high expression of miR‑124a was prolonged relative to patients with low expression of miR‑124a. The expression levels of miR‑124a were associated with clinical characteristics, including lymph‑node metastasis, tumor differentiation, tumor node metastasis (TNM) stage and diameter. Frequently,
Correspondence to: Dr Yu‑Shui Ma, Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yanchang Road, Shanghai 200072, P.R. China E‑mail: [email protected] Dr Qing‑Hua Zeng, Department of Respiratory, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Road, Nanchang 330006, P.R. China E‑mail: [email protected] *
Contributed equally
Key words: microRNA‑124, non‑small cell lung cancer, chemotherapy, overall survival, disease‑free survival, biomarker, prognosis
lymph‑node metastasis, TNM stage, diameter and lack of chemotherapy have been associated with a worse prognosis in patients. In addition, the present study identified that high expression of miR‑124awith chemotherapy may increase OS. In conclusion, the current study demonstrated that miR‑124a was downregulated in NSCLC, and miR‑124a was a potential prognostic tumor biomarker response to chemotherapy. Introduction Lung cancer is one of the most common malignancies and is the major cause of cancer‑associated mortality, accounting for ~1.38 million deaths each year (1,2). Of all lung carcinomas, non‑small cell lung cancer (NSCLC) accounts for ~70‑85% (3). Although there have been recent advances in diagnosis and treatment, the prognosis of lung cancer is still unfavorable and the 5‑year overall survival (OS) rate remains
